Actinogen Medical Limited – 1HFY26 Clinical Milestones and Financial Update
Actinogen Medical Limited (ASX: ACW) delivered substantial operational progress during the half year ended 31 December 2025, underpinned by the successful completion of enrolment in its 247-patient XanaMIA Phase 2b/3 Alzheimer’s trial. The independent Data Monitoring Committee endorsed continuation of the study without changes following a favourable interim safety and futility assessment, supporting the robustness of the clinical program.
Research and development expenditure increased to AU$8,902,759, reflecting intensified clinical activity, while the net loss after tax for the period was AU$11,346,952. Cash and cash equivalents were AU$6,531,460 as at 31 December 2025, with subsequent capital initiatives enhancing funding visibility. Topline data from the XanaMIA trial are expected in November 2026, positioning Xanamem as a differentiated oral candidate targeting cortisol modulation in Alzheimer’s disease.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Actinogen Medical Limited – 1HFY26 Clinical Milestones and Financial Update
Actinogen Medical Limited (ASX: ACW) delivered substantial operational progress during the half year ended 31 December 2025, underpinned by the successful completion of enrolment in its 247-patient XanaMIA Phase 2b/3 Alzheimer’s trial. The independent Data Monitoring Committee endorsed continuation of the study without changes following a favourable interim safety and futility assessment, supporting the robustness of the clinical program.
Research and development expenditure increased to AU$8,902,759, reflecting intensified clinical activity, while the net loss after tax for the period was AU$11,346,952. Cash and cash equivalents were AU$6,531,460 as at 31 December 2025, with subsequent capital initiatives enhancing funding visibility. Topline data from the XanaMIA trial are expected in November 2026, positioning Xanamem as a differentiated oral candidate targeting cortisol modulation in Alzheimer’s disease.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au